Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety
Hematology Reports · 03.08.2026 · 18 (4) · 54
DOI: 10.3390/hematolrep18040054 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Hematology Reports, online erschienen am 03.08.2026. Verfasst von Jerry Qi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Teclistamab is a B-cell maturation antigen (BCMA)-directed bispecific antibody approved for relapsed or refractory multiple myeloma (RRMM). Although prior analyses have summarized teclistamab outcomes, some have included combination regimens or broader comparative studies. Given the expanding real-world experience with teclistamab, we conducted a systematic review and meta-analysis focused on teclistamab monotherapy in RRMM.
Methods
We performed a systematic review and meta-analysis of clinical trials and retrospective real-world studies evaluating teclistamab monotherapy in RRMM. The primary endpoint was overall response rate (ORR). Secondary endpoints included complete response (CR), overall mortality rate (OMR), mortality due to multiple myeloma progression, teclistamab-attributed mortality, adverse event-related mortality, grade ≥3 cytokine release syndrome (CRS), grade ≥3 immune effector cell-associated neurotoxicity syndrome (ICANS), and other grade ≥3 adverse events. Pooled proportions were estimated using random-effects models.
Results
Twelve studies including 761 patients were analyzed, comprising two clinical trials and ten real-world retrospective cohorts. The pooled ORR was 60.9%, and the pooled CR rate was 25.2%. The pooled OMR was 26.9%, with mortality due to myeloma progression of 23.9%, adverse event-related mortality of 8.1%, and teclistamab-attributed mortality of 3.3%. Severe (grade ≥3) CRS and ICANS were uncommon, with grade ≥3 events occurring in 1.7% and 3.1%, respectively. Grade ≥3 infections occurred in 28.3%. Common grade ≥3 hematologic adverse events included lymphopenia, neutropenia, anemia, and thrombocytopenia.
Conclusions
Teclistamab monotherapy demonstrates meaningful clinical activity and a manageable immune toxicity profile in heavily pretreated RRMM. However, severe infections and hematologic toxicities remain important clinical considerations, supporting the need for close monitoring, infection prevention, and supportive care during therapy.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA.
- Department of Medicine, University of California, San Francisco, Fresno Campus, 155 N. Fresno Street, Fresno, CA 93701, USA.
- Division of Transplant, Cellular Therapy, and Hematological Malignancies, Department of Medicine, Loma Linda University Medical Center, 11234 Anderson Street, Loma Linda, CA 92354, USA.
ORCID-Profile: Jerry Qi, Pranati Shah
Zitieren
APA
Qi, J., Park, D., Shah, P., & Akhtari, M. (2026). Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety. Hematology Reports, 18(4), 54. https://doi.org/10.3390/hematolrep18040054
Vancouver
Qi J, Park D, Shah P, Akhtari M. Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety. Hematology Reports. 2026;18(4):54. doi:10.3390/hematolrep18040054
BibTeX
@article{Qi2026,
author = {Qi, Jerry and Park, Daniel and Shah, Pranati and Akhtari, Mojtaba},
title = {Teclistamab Monotherapy in Relapsed or Refractory Multiple Myeloma: A Real-World Focused Systematic Review and Meta-Analysis of Efficacy and Safety},
journal = {Hematology Reports},
year = {2026},
volume = {18},
number = {4},
pages = {54},
doi = {10.3390/hematolrep18040054}
}
EUVIMED